CHALLENGE

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is one of the most common endocrine disorders affecting women of reproductive age and one of the leading causes of infertility.

Despite its high prevalence, current treatments focus primarily on managing symptoms rather than addressing the underlying causes of the syndrome.

This limitation, combined with the complexity and variability of PMOS, makes the condition particularly challenging to manage, especially in adolescents and young women, and may lead to long-term complications.

In this context, SPIOMET4HEALTH aims to advance towards a treatment approach based on the mechanisms underlying the syndrome.

SOLUTION

SPIOMET4HEALTH proposes an innovative approach focused on the pathophysiology of the syndrome through the development and validation of a specific therapeutic combination in a single formulation.

The project is evaluating a treatment that targets the metabolic and hormonal mechanisms involved in PMOS, with the aim of providing a more effective alternative to current approaches.

This approach represents a step towards treatments that address the underlying causes of the syndrome, with the potential to improve patients’ quality of life.

RESULTS

The project brings together a multidisciplinary consortium of research centres, hospitals and specialised healthcare organisations from several European countries. As part of the project, a multicentre clinical trial has been conducted in Spain, Italy, Denmark, Austria, Norway and Türkiye, generating a robust body of data on the efficacy and safety of the treatment across a diverse patient population.

These results will help validate a new therapeutic approach and improve the management of PMOS in clinical practice.